MetLife Investment Management LLC Lowers Position in Teleflex Incorporated $TFX

MetLife Investment Management LLC decreased its position in Teleflex Incorporated (NYSE:TFX) by 93.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 835 shares of the medical technology company’s stock after selling 11,456 shares during the period. MetLife Investment Management LLC’s holdings in Teleflex were worth $115,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TFX. MassMutual Private Wealth & Trust FSB raised its position in Teleflex by 103.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 100 shares during the last quarter. True Wealth Design LLC raised its position in Teleflex by 62.3% during the fourth quarter. True Wealth Design LLC now owns 271 shares of the medical technology company’s stock worth $48,000 after acquiring an additional 104 shares during the last quarter. Signaturefd LLC raised its position in Teleflex by 38.3% during the first quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock worth $60,000 after acquiring an additional 120 shares during the last quarter. Empirical Finance LLC raised its position in Teleflex by 7.9% during the first quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock worth $234,000 after acquiring an additional 124 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in Teleflex by 30.2% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 556 shares of the medical technology company’s stock worth $77,000 after acquiring an additional 129 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TFX. Mizuho lifted their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Royal Bank Of Canada boosted their price objective on shares of Teleflex from $130.00 to $135.00 and gave the company a “sector perform” rating in a research report on Friday, August 1st. Wells Fargo & Company cut their price objective on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Finally, Wall Street Zen raised shares of Teleflex from a “buy” rating to a “strong-buy” rating in a research report on Sunday. One investment analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Teleflex currently has an average rating of “Hold” and an average target price of $141.57.

Teleflex Price Performance

TFX opened at $130.30 on Thursday. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. Teleflex Incorporated has a 52-week low of $108.90 and a 52-week high of $249.90. The company has a 50 day moving average of $120.50 and a two-hundred day moving average of $127.07. The company has a market cap of $5.76 billion, a P/E ratio of 30.66, a P/E/G ratio of 1.82 and a beta of 1.08.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The company had revenue of $780.90 million during the quarter, compared to the consensus estimate of $771.53 million. During the same period in the previous year, the firm earned $3.42 earnings per share. Teleflex’s revenue for the quarter was up 4.2% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.0%. The ex-dividend date is Friday, August 15th. Teleflex’s payout ratio is currently 32.00%.

Insider Activity at Teleflex

In other Teleflex news, Director Andrew A. Krakauer acquired 1,000 shares of the firm’s stock in a transaction on Tuesday, August 5th. The stock was bought at an average cost of $115.25 per share, for a total transaction of $115,250.00. Following the completion of the purchase, the director directly owned 7,192 shares in the company, valued at $828,878. This represents a 16.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Stuart A. Randle acquired 1,000 shares of the firm’s stock in a transaction on Tuesday, August 5th. The shares were acquired at an average price of $115.86 per share, with a total value of $115,860.00. Following the completion of the purchase, the director owned 7,547 shares of the company’s stock, valued at $874,395.42. This trade represents a 15.27% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 5,500 shares of company stock valued at $633,590 over the last quarter. Company insiders own 1.40% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.